Furthermore, cells lacking SphK2 had a reduced capacity to induce ALL driven by the BCR/ABL1 fusion gene in WT mice, while SphK2 inhibition synergized with imatinib treatment of BCR/ABL1+ ALL in vitro and in vivo [30]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.